The direct-to-consumer telehealth company said the workforce reduction is unrelated to its weight-loss drug sector.

Hims & Hers Health (NYSE: HIMS), a telehealth platform, experienced an 8% increase in its stock on Friday, May 30th, ...

By Amina Niasse NEW YORK (Reuters) -Telehealth platform Hims & Hers will cut 68 employees, or about 4% of its workforce, as ...

Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.

Hims & Hers is evolving beyond its original focus, aggressively expanding into peptides and GLP-1. Read why I reiterate my ...

Investors are buying Hims & Hers Health ( HIMS 10.09%) stock hand over fist after the mail-order drugs company reported an earnings miss but a sales beat last night. But they're selling off shares of ...

Hims & Hers Health continues to fire on all cylinders as a business. Click here to read why HIMS stock is a Buy.

Just 14 stocks with market caps above $1 billion have doubled so far this year. They probably aren't the winners you would ...

Hims to cut 4% of workforce amid ban on weight ... cancer risks Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related cancers ...

Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of ...

Hims & Hers teams up with Novo Nordisk to bundle Wegovy into a $599/month telehealth care plan. Investors see Amazon-like potential as Hims scales affordable healthcare through platform-based ...

It's plainly apparent that Novo Nordisk has had May 22 circled its calendar since February, when the FDA began the countdown ...